News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    

BioPharm Executive - Golden Handshakes
Galenica (GALN.SW) to Acquire Bay Area's Relypsa (RLYP) for $1.53 Billion 7/22/2016
Cambridge Startup Jounce Lands $2.5 Billion Deal With Biotech's Best Friend Celgene (CELG) 7/20/2016
Bayer (BAY) Sweetens Deal to $54.7 Billion for Monsanto (MON) 7/15/2016
Already Partners, Bayer (BAY) and X-Chem Whip Up a New R&D Pact Worth $528 Million 7/12/2016
Vertex (VRTX) and Moderna Hammer Out $315 Million+ Deal to Treat Cystic Fibrosis Using mRNA Technology 7/6/2016
Bay Area's IMPAX Labs (IPXL) Plunks Down $586 Million for a Chunk of Teva (TEVA) and Allergan (AGN)’s Generics Portfolio 6/21/2016
Struggling Eleven Bio (EBIO) Forges Deal Worth $270 Million with Pharma Giant Roche (RHHBY) 6/13/2016
Walgreens Breaks Ties With Theranos, Will Shutter All 40 Wellness Centers 6/13/2016
Days After Judge Overturns Merck & Co. (MRK)-Gilead (GILD) Lawsuit, Merck Acquires Bay Area's Afferent Pharma for $1.2 Billion 6/10/2016
Abbott (ABT) Tries to Bail Out of $5.8 Billion Deal as Alere (ALR) Faces Bribery Probes, But it Won't Be Easy 6/3/2016
Amid Shareholder Pressure, Bayer AG (BAYZF) Makes Formal $62 Billion Bid for Monsanto  (MON) 5/24/2016
Agios (AGIO), Celgene (CELG) Hammer Out $1 Billion+ Metabolic Immuno-Oncology Deal 5/19/2016
MacroGenics (MGNX) Wrangles Cancer Deal Worth $755 Million Out of Johnson & Johnson (JNJ) 5/19/2016
In Another Small Deal, Pfizer (PFE) Slams Down $5.2 Billion for Bay Area Drugmaker Anacor (ANAC) 5/17/2016
Medivation (MDVN) Takeover Saga Takes Another Turn, Rumored to Open Books to Amgen (AMGN) and Pfizer (PFE) 5/11/2016
A Day After The Pfizer (PFE)-Allergan (AGN) Deal Dies, Allergan Inks Potential $3.3 Billion Alzheimer’s Deal with Heptares 4/11/2016
Pfizer (PFE) Formally Calls Off $160 Billion Allergan (AGN) Deal 4/7/2016
Incyte (INCY) Pays $35 Million Upfront to Eli Lilly (LLY) for Rights to GVHD Drug Ruxolitinib 4/6/2016
Massachusetts' Tesaro (TSRO) Inks $450 Million Prostate Cancer Deal with Drug Giant Johnson & Johnson (JNJ) 4/6/2016
Gilead (GILD) Finally Makes a Buy, Snaps Up Massachusetts' Nimbus Apollo in $1.2 Billion Deal 4/4/2016
Bristol-Myers Squibb (BMY) Snaps Up Padlock Therapeutics in Deal Up to $600 Million, Locking Up Rheumatoid Arthritis Program 3/24/2016
Origin Technologies and Thermo Fisher Scientific (TMO) in Acquisition Love Triangle with Affymetrix (Santa Clara, California) (AFFX) 3/23/2016
Bay Area Startup DiCE Molecules Inks Small Molecule Deal Worth Up to $2.3 Billion with Sanofi (SNY) 3/17/2016
SoCal's Kite Pharma (KITE) Grabs a Clinical Trial Cancer Deal with Genentech (RHHBY) 3/17/2016
Drug Giant Roche (RHHBY) Wagers Up to $1 Billion on Blueprint Medicines (BPMC)'s Cancer Immunotherapy Platform 3/16/2016
Corvidia Therapeutics Bags $26 Million and a Licensing Deal with AstraZeneca PLC (AZN) 2/18/2016
Mylan (MYL) Snaps Up Swedish Drugmaker MEDA in $7.2 Billion Deal 2/11/2016
Hikma (HIK.L) Halves Cash Offer for Boehringer Ingelheim's Roxane, Will Pay $575 Million Less 2/10/2016
Deal Spree for AstraZeneca PLC (AZN) Pretty Much Over as CEO Says "We Have What We Need to Have" 2/4/2016
Takeda (TKPYY) Wagers $1 Billion+ More on Mersana Therapeutics' Antibody Program 2/4/2016
GlaxoSmithKline (GSK) CEO Might Consider Breakup After Novartis AG (NVS) Deal Completion 1/14/2016
2015 Was a Record Breaker for M&A in Pharma, Medical and Biotech with Deals Worth $575 Billion 1/14/2016
Arena (ARNA) Scores a $262 Million Schizophrenia Deal with Boehringer Ingelheim 1/13/2016
After a 6-Month Courtship, Baxalta (BXLT) Finally Says Yes to $32 Billion Shire (SHPG) Marriage Proposal 1/12/2016
Tiny Surface Oncology Gets $170 Million Upfront in Next-Gen Cancer Deal with Novartis AG (NVS) 1/11/2016
Pharma Giant AstraZeneca PLC (AZN) in Advanced Talks to Buy Acerta Pharma for $5 Billion+ 12/15/2015
Dow Chemical  (DOW), DuPont (DD) Could Merge, Massive Layoffs Could Follow 12/11/2015
Tiny Boston Startup SQZ Biotech Scores a $500 Million+ Cell Therapy Pact with Roche (RHHBY) 12/7/2015
Roaring Zymeworks Inks Antibody Pact Worth $440 Million+ with GlaxoSmithKline (GSK) 12/3/2015
Pfizer (PFE) Marries Allergan (AGN) in $160 Billion Deal With Pfizer’s Read to Stay as CEO and Chairman 11/25/2015
Pfizer (PFE), Servier Snap Up Right to Cellectis (ALCLS)' Blood Cancer Therapy in $338 Million+ Deal 11/19/2015
Mylan (MYL) Spurned Again as Perrigo (PRGO) Rejects $26 Billion Takeover Bid 11/13/2015
Johnson & Johnson (JNJ) Unit, Hanmi Pharma Ink Diabetes and Obesity Pact Worth $915 Million 11/9/2015
In Attempt to Bolster Sagging Diabetes Revenue, Sanofi (SNY) Inks Deal with Hanmi Pharma Worth $4.2 Billion 11/6/2015
Vertex (VRTX) Coughs Up $105 Million Upfront to CRISPR for Gene Editing Pact 10/26/2015
AbbVie (ABBV) and Alphabet's Ambitious Plan to Battle Immortality 10/20/2015
SSF's Five Prime (FPRX) Wrangles Immuno-Oncology Deal Worth $1.74 Billion Out of Bristol-Myers Squibb (BMY) 10/16/2015
Eli Lilly (LLY), China-based Innovent Biologics Expand Cancer Drug Collaboration With $1 Billion PD-1 Pact 10/12/2015
Arvinas Inks $300 Million Deal With Genentech (RHHBY) Over Protein Degradation Technology 10/2/2015
Perrigo (PRGO) Rejects Unsolicited Mylan (MYL) Bid 9/17/2015
Celgene (CELG), Nurix Team Up on $150M Drug Development Deal 9/17/2015
Amgen (AMGN) Scoops Up Dezima Pharma for $300 Million in Cash 9/17/2015
Biogen (BIIB) Forges $544M Deal to Take on Celgene (CELG) With a Rival Autoimmune Drug 9/11/2015
AstraZeneca PLC (AZN) Inks $445 Million Psoriasis Drug Pact With Valeant (VRX) After Amgen (AMGN) Bows Out 9/2/2015
BioMarin (BMRN) Sells Phase III Breast Cancer Drug to Medivation (MDVN) for $570 Million 8/25/2015
In Puzzling Move, Novartis AG (NVS) Offers $1 Billion for GlaxoSmithKline (GSK)’s Ofatumumab for Auto-Immune Diseases 8/25/2015
Bay Area's Raptor (RPTP) Beefs Up Portfolio With $453 Million Deal for Quinsair 8/21/2015
Valeant (VRX) Acquires Female Sex Drive Drug Maker Sprout for $1 Billion 8/21/2015
Genmab A/S (GEN.CO), Novo Nordisk A/S (NVO) Strike $452 Million+ DuoBody Tech Pact 8/14/2015
Teva (TEVA) Snaps Up Allergan (AGN) Generics for $40.5 Billion, Ends Pursuit of Mylan (MYL) 7/27/2015
Depomed (DEPO) Gets Sweetened $33 Per Share Offer From Horizon Pharma (HZNP) 7/21/2015
New Restructuring Leads to the Birth of Sanofi (SNY) and Its Plan to Expand 7/20/2015
Celgene (CELG) Swallows Up SoCal's Receptos (RCPT) in $7.2 Billion Deal 7/17/2015
AGTC (AGTC) Catapults Premarket on $1 Billion+ Eye Disease Pact With Biogen (BIIB) 7/6/2015
Johnson & Johnson (JNJ), Roche (RHHBY) Allegedly Circle GlaxoSmithKline (GSK) as Takeover Speculation Intensifies 6/26/2015
Almac Discovery Wrangles R&D Deal Worth $363.5 Million+ From Genentech (RHHBY) 6/16/2015
Celgene (CELG) Shells Out $82.5 Million in Cash for Portfolio, Option to Buy Lycera 6/9/2015
Tiny Startup Unum Forges $645 Million Pact With Seattle Genetics (SGEN) 6/9/2015
Tiny Parion Sciences Wrangles Lung Pact Worth $1.2 Billion From Vertex (VRTX) 6/8/2015
Alexion (ALXN) Plunks Down $8.4 Billion for Synageva BioPharma (GEVA), As Dealmaking Roars 5/7/2015
$60 Million Juno Therapeutics (JUNO) Deal Pushes Fate Therapeutics (FATE) Up 80% in Premarket Trading 5/7/2015
Isis Pharma (ISIS) Inks $155 Million Bayer (BAY) Deal Just After Good News From Biogen (BIIB) Collaboration 5/5/2015
Celgene (CELG) Slaps Down $450 Million Upfront for AstraZeneca PLC (AZN)'s Prized Immunotherapy Blood Cancer Drug 4/24/2015
Innate Pharma (IPH.PA ) Strikes Cancer Pact Worth $1.275 Billion With Pharma Giant AstraZeneca PLC (AZN) 4/24/2015
BREAKING: Perrigo (PRGO) Rejects $30B Mylan (MYL) Bid, Says Deal "Substantially Undervalues" Irish Firm 4/21/2015
Tiny Curadev Wrangles a $555 Million Pact With Drug Giant Roche (RHHBY) 4/20/2015
uniQure (QURE) Soars After Bristol-Myers Squibb (BMY) Bets $1 Billion on Gene Therapy Platform 4/7/2015
Another Day, Another $456 Million Cancer Pact for Eli Lilly (LLY) 3/23/2015
AstraZeneca PLC (AZN), Daiichi Sankyo in $825 Million Drug Tie-Up 3/19/2015
Eli Lilly (LLY), Hanmi Pharma Forge $690 Million Autoimmune Pact 3/19/2015
AbbVie (ABBV) Overpaid in Pharmacyclics (PCYC) Deal, For Only 50% Rights to Imbruvica: Analyst 3/6/2015
Bristol-Myers Squibb (BMY) Bets $975 Million on Bavarian Nordic (BAVA.CO)'s Prostate Cancer Vaccine 3/5/2015
Spending Spree Continues as Valeant (VRX) Officially Snags Salix (SLXP) for $14.5 Billion 2/23/2015
Pfenex (PFNX), Hospira Pursue Lucentis Biosimilar in $342 Million Pact 2/11/2015
AstraZeneca PLC (AZN) Who? Pfizer (PFE) Snatches Up Hospira for $17 Billion Cash 2/6/2015
AstraZeneca PLC (AZN) Slams Down $600 Million for Actavis (ACT) Lung Unit 2/5/2015
Mylan (MYL), Theravance (THRX) Partner Up for $265 Million COPD Pact 2/2/2015
The New Billion Dollar Tekmira (TKMR) Includes Promising Hep B Drug 1/20/2015
Merck & Co. (MRK) Jumps Into RNA Frenzy With $100 Million Bet on Moderna Therapeutics, Inc. 1/14/2015
Tiny Vedanta Biosciences Forges $241 Million+ Pact With Johnson & Johnson (JNJ) 1/14/2015
Shire (SHPGY) Officially Snaps Up NPS Pharmaceuticals, Inc. (NPSP) in $5.2 Billion Deal 1/12/2015
Roche (RHHBY) Pays $1.03 Billion for Majority Stake in Foundation Medicine, Inc. (FMI) 1/12/2015
Opko Health, Inc. (OPK) Rockets After Striking Deal Worth $570 Million With Pfizer (PFE) 12/17/2014
Oncothyreon Inc. (ONTY) Strikes $300 Million Cancer Pact With Array BioPharma, Inc. (ARRY) 12/15/2014
Drug Giant Merck & Co. (MRK) Buys Cubist Pharmaceuticals, Inc. (CBST) For $9.5 Billion 12/11/2014
Spark Therapeutics Strikes $280 Million Hemophilia B Pact With Pfizer (PFE) 12/9/2014
GeNeuro, Servier Ink $455M MS Drug Pact 12/2/2014
Actavis (ACT) Agrees To Buy Allergan (AGN) For $66 Billion 11/18/2014
Pfizer (PFE), Merck KGaA (MKGAF.PK) Strike A $2.9B Deal To Develop Cancer Tumor Treatment 11/18/2014
Astellas Pharma Inc. (ALPMY), Proteostasis Therapeutics, Inc. Forge $1.2 Billion Genetic Disease Drug Pact 11/5/2014
Bristol-Myers Squibb (BMY) Strikes Deal Worth $444 Million With Galecto Biotech 11/4/2014
Five Prime Therapeutics, Inc. (FPRX) Snags An Expanded Deal Worth $196.3 Million With GlaxoSmithKline (GSK) 10/24/2014
SSF's Sutro Biopharma Forges $1 Billion+ And Option To Buy Pact With Celgene (CELG) 10/23/2014
Genentech (RHHBY), NewLink Genetics Strike $1 Billion+ Cancer Deal 10/21/2014
AbbVie (ABBV) Officially Abandons Shire 10/21/2014
Oxford BioMedica PLC (OXB.L) Inks Transformational $90 Million Deal With Novartis AG (NVS) 10/10/2014
South San Francisco's Sutro Biopharma Forges $375 Million Antibody Drug Pact With Merck KGaA (MKGAF.PK) 9/17/2014
Eli Lilly (LLY) Bets $500 Million On AstraZeneca PLC (AZN)’s Alzheimer's Drug 9/17/2014
More Than 35% Of Allergan Inc. (AGN) Investors Demand Special Meeting; Support For Valeant (VRX) Merger Grows 9/12/2014
Seattle Genetics, Inc. (SGEN), Genmab A/S (GEN.CO) Partner In $211 Million Antibody-Drug Pact 9/10/2014
AbbVie (ABBV) Hands Over $275 Million Upfront For Infinity Pharmaceuticals Inc. (INFI)’s Blood Cancer Drug; Deal Could Be Worth $805 Million 9/5/2014
Roche (RHHBY) Pays $8.3 Billion For Bay Area's InterMune (ITMN), Pledges To Keep Employees 8/26/2014
Pfizer (PFE) Eyes Possible Actavis (ACT) Bid Whilst Weighing Next Steps Over AstraZeneca PLC (AZN) 8/22/2014
Novartis AG (NVS), GlaxoSmithKline (GSK) Reshape Pharma With Game-Changing $14.5 Billion Deal 8/12/2014
Sanofi (France) (SAN.PA) To Pay MannKind Corporation (MNKD) Up To $925 Million For Inhaled Insulin 8/12/2014
Sanofi (France) (SAN.PA), Immune Design Corporation (IMDZ) Strike Food Allergy Deal Worth $168 Million+ 8/7/2014
Mylan Inc. (MYL)'s Overseas Move Will Lower Tax Rate 7/23/2014
AbbVie (ABBV) Finally Clinches Shire For $54 Billion 7/21/2014
Novartis AG (NVS), Google Inc. Strike Smart Contact Lenses Pact 7/15/2014
Genentech (RHHBY) To Pay Up To $1.7 Billion For San Diego Biotech Firm Seragon Pharmaceuticals 7/7/2014
Massachusett's bluebird bio (BLUE) Snaps Up Pregenen For Up To $139.9 Million 7/2/2014
Tapping University of California, San Francisco (UCSF) Invention, Roche (RHHBY) To Partner With San Diego Startup Inception Sciences, Versant Ventures To Form New Multiple Sclerosis Company 6/24/2014
Major Drugmakers Like AstraZeneca PLC (AZN), GlaxoSmithKline (GSK). And Johnson & Johnson (JNJ) Link Up With Academia In Huge $27 Million UK Dementia Project 6/20/2014
AstraZeneca PLC (AZN) Beefs Up Pipeline With $232 Million Synairgen plc Asthma Deal 6/12/2014
Merck & Co., Inc. (MRK) Snags Cambridge's Idenix Pharmaceuticals, Inc. (IDIX) For $3.85 Billion 6/11/2014
Adaptimmune Ltd., GlaxoSmithKline (GSK) Strike $350 Million Cancer Immunotherapy Pact 6/2/2014
Neurotez, Inc., GCA Therapeutics Strike $102.5 Million+ Alzheimer's Pact 5/21/2014
AstraZeneca PLC (AZN) Rejects Pfizer Inc. (PFE)'s Final Offer 5/20/2014
Ophthotech Corporation (OPHT) May Pocket $1 Billion From Eye Drug Deal With Novartis AG (NVS), Ophthotech Stock Up +24.48% At Market Close (May 20, 2014) 5/20/2014
Valeant Pharmaceuticals International (VRX) Will Sweeten $46 Billion Allergan Inc. (AGN) Bid 5/14/2014
Lundbeck Inc. (LUN.CO) Swallows Up Chelsea Therapeutics, Inc. (CHTP) In Deal Worth $658 Million 5/9/2014
Pfizer Inc. (PFE) Still Wants AstraZeneca PLC (AZN) After $98.7 Billion Bid Rejected 4/29/2014
Celgene Corporation (CELG) Antes Up $710 Million Upfront For Phase 3-Ready Crohn's Disease Drug 4/24/2014
Allergan Inc. (AGN) Curls Up Into Poison-Pill Position In Wake Of Valeant Pharmaceuticals International (VRX), Ackman Acquisition Bid 4/23/2014
FORMA Therapeutics, Inc. Picks Up Another $225 Million, And A Potential Buyout From Celgene (CELG) 4/2/2014
Baxter International, Inc. (BAX) To Split Into Two Companies, Spins Off $6 Billion Biotech Biz 3/28/2014
MedImmune (AZN), MD Anderson Cancer Center Agree To Launch Moon Shot At Cancer 3/20/2014
Five Prime Therapeutics, Inc. (FPRX), Bristol-Myers Squibb Company (BMY) Strike $350 Million Immuno-Oncology Pact 3/18/2014
Charles River Laboratories (Massachusetts) Shells Out $179 Million Cash To Buy Galapagos NV (GLPG.BR)'s CRO Services Division 3/13/2014
Top Biopharmas Such As Abbott Laboratories (ABT) And GlaxoSmithKline (GSK) Still Betting On "Messed Up" Indian Drugs Market 3/12/2014
Novartis AG (NVS) Chairman Rules Out Merger With Roche (RHHBY) 3/3/2014
Actavis (ACT) Bags Rival, Forest Laboratories, Inc. (FRX), For $25 Billion; Forest Stock Rockets +27.52% At Market Close (February 18, 2014) 2/19/2014
CoStim Pharmaceutical Buyout Bolsters Novartis AG (NVS)'s Cancer Portfolio 2/18/2014
Mallinckrodt Pharmaceuticals (MNK) Adds Pain Drug With $1.3 Billion Cash Cadence Pharmaceuticals, Inc. Buyout 2/11/2014
Eli Lilly and Company (LLY), Pfizer Inc. (PFE) And Eight Other Rivals Join The National Institutes of Health (NIH) In $230 Million Deal To Search For New Drugs 2/5/2014
Ablynx (ABLYF), Merck & Co., Inc. (MRK) Forge Cancer Pact Worth $2.3 Billion 2/3/2014
Nantbioscience Scores $75 Million Cancer Deal With Celgene Corporation (CELG) 1/16/2014
Regeneron (REGN), Bayer HealthCare (BAY) Forge Pact Worth $65 Million+ To Co-develop Wet AMD Drug 1/14/2014
Jazz Pharmaceuticals plc (JAZZ) Forges Pact Worth $397 Million For Aerial BioPharma's Sleepiness Drug 1/13/2014
Santaris Pharma A/S, Roche (RHHBY) Strike $148 Million+ Alliance To Design And Develop RNA-Targeted Drugs 1/10/2014
Biogen Idec, Inc. (Massachusetts) (BIIB) May Pay Sangamo BioSciences, Inc. (SGMO) As Much As $320 Million For Blood Drugs; SGMA Soars +38.32% At Market Close (January 9, 2014) 1/9/2014
Roche (RHHBY) Inks Deal Worth Up To $600 Million For Prothena Corporation plc's Parkinson's Drug 12/13/2013
Biogen Idec, Inc. (Massachusetts) (BIIB), Proteostasis Therapeutics, Inc. Hammer Out $200 Million+ Pre-Clinical Alzheimer's Pact 12/9/2013
AstraZeneca PLC (AZN) Said To Be Eyeing Forest Laboratories, Inc. (FRX) Takeover Bid 12/4/2013
Roche (RHHBY), Molecular Partners AG Ink $1 Billion+ Cancer Pact 12/4/2013
Celgene Corporation (CELG) Smacks Down $177 Million Upfront For OncoMed Pharmaceuticals, Inc. (OMED)'s Stem Cell Drugs, Deal Is Potentially Worth $3.3 Billion; OMED Stock Up 97.86% at Market Close (December 3, 2013) 12/4/2013
immatics biotechnologies GmbH, Roche (RHHBY) Ink Cancer Pact Worth Up To $1 Billion 11/13/2013
Shire To Pay $4.2 Billion For Rare Disease Firm ViroPharma Incorporated (VPHM) 11/11/2013
ImmunoGen, Inc. (IMGN) Is On A Roll, Inks Fifth New License Agreement Of 2013 11/11/2013
Salix Pharmaceuticals, Ltd. (SLXP) Bags Santarus Inc. (SNTS) for $2.6 Billion to Beef Up Gastro Drug Line-Up 11/8/2013
Roche (RHHBY) to Pay Polyphor Up to $548 Million for Superbug Antibiotic 11/4/2013
Startup NextCODE Health, Launches Operations With $15 Million in Venture Financing 10/23/2013
Amgen (AMGN) Acquires Filgrastim Franchise Rights From Roche (RHHBY) in 100 Markets 10/23/2013
PDL BioPharma, Inc. (PDLI) Snatches Up Depomed, Inc. (DEPO)'s Diabetes Portfolio for $240.5 Million 10/22/2013
AmpliPhi Biosciences (TGEN) Signs Exclusive License With University of Leicester, UK to Develop Bacteriophage Therapies 10/17/2013
AstraZeneca PLC (AZN)'s MedImmune (AZN) Takes Over Spirogen Ltd. for Up to $400 Million to Bolster Oncolology Portfolio 10/15/2013
Ablynx (ABLYF) Scores $840 Million Inflammatory Drug Pact With AbbVie (ABBV); Ablynx Stock Rises 24.73% at Market Close (September 23, 2013) 9/23/2013
Clovis Oncology (CLVS) Looking to Sell Itself 9/18/2013
Roche (RHHBY), Inovio Pharmaceuticals (INO) Strike Vaccines Pact Worth $422.5 Million 9/11/2013
Biogen Idec, Inc. (Massachusetts) (BIIB) Makes $100 Million Upfront Payment in R&D Neurological Disorders Pact With Isis Pharmaceuticals, Inc. (ISIS) 9/9/2013
Japan's Otsuka Pharmaceutical Co., Ltd. Shells Out $886 Million for U.S. Cancer Firm Astex Pharmaceuticals (ASTX) 9/5/2013
Amgen (AMGN) Finally Reaches Deal to Buy Onyx Pharmaceuticals, Inc. (ONXX) for $10.4 Billion, AMGN Stock Rockets +7.72% on Monday @ Market Close (August 26, 2013) 8/26/2013
Adimab LLC. Adds Celgene Corporation (CELG) to Its Growing List of Big-Name Drugmaking Partners 8/20/2013
Shire plc Hires Adviser on Takeover Threat 8/20/2013
Array BioPharma, Inc. (ARRY) Says Amgen (AMGN) Ends Agreement, to Cut 20 Percent of Jobs 8/9/2013
Jazz Pharmaceuticals plc (JAZZ) and Alkermes plc (ALKS) are Seen as Next Targets Amid Irish Deal Frenzy: Real M&A 8/6/2013
Transition Therapeutics Inc. (TTH.TO) Buys Rights to Eli Lilly and Company (LLY)'s Arthritis Drug; Transition May be Eligible for $130 Million+ 7/24/2013
Pfizer Inc. (PFE) Not Moving Forward With Onyx Pharmaceuticals, Inc. (ONXX) Bid: Sources 7/19/2013
Quest Diagnostics Inc. (DGX) Sells Ibrutinib Royalty Rights to Royalty Pharma for $485 Million in Cash 7/18/2013
Spectrum Pharmaceuticals, Inc. (SPPI) Snaps Up Talon Therapeutics, Inc. (TLON.OB) in $206.3 Million Deal 7/17/2013
Array BioPharma, Inc. (ARRY), Loxo Oncology Strike $434 Million+ Cancer Pact 7/11/2013
Johnson & Johnson (JNJ) to Buy Aragon Pharmaceuticals, Inc. for Up to $1 Billion 6/17/2013
AstraZeneca PLC (AZN) and NGM Biopharmaceuticals, Inc. Form Diabetes/Obesity Partnership 6/17/2013
Johnson & Johnson (JNJ) Sells Final Stake in Elan Corporation PLC (ELN) for $332 Million 6/14/2013
Cytokinetics, Inc. (CYTK), Amgen (AMGN) Expand $75 Million Development Deal Into Japan 6/12/2013
AstraZeneca PLC (AZN) in Deal for Pearl Therapeutics Worth Up to $1.15 Billion 6/11/2013
Actavis (ACT) Nabs Warner Chilcott, PLC (WCRX) for $8.5 Billion 5/20/2013
AbbVie (ABBV), Galapagos NV (GLPG.BR) Ink $50 Million Crohn's Disease Pact 5/17/2013
AstraZeneca PLC (AZN), Cubist Pharmaceuticals, Inc. (CBST), Astellas Pharma Inc. (YPH.BE) Said to Make Bids for Optimer Pharmaceuticals, Inc. (OPTR) 5/15/2013
Elan Corporation PLC (ELN) Bets $1 Billion on Theravance, Inc. (THRX) Drugs; Move to Spurn Its Hostile Suitor? 5/13/2013
Concert Pharmaceuticals, Inc. and Celgene Corporation (CELG) Tie the Knot in a $300 Million Tech Deal 5/6/2013
Roche (RHHBY), Ascletis, Inc. to Collaborate on Hepatitis C Drugs for China 4/15/2013
GlaxoSmithKline (GSK) Targets "Electroceuticals" for Potential New Therapies 4/11/2013
GlaxoSmithKline (GSK) and A*STAR's Institute of Chemical Engineering and Sciences to Develop New Medicines for Emerging Markets 4/9/2013
Roche (RHHBY) and Isis Pharmaceuticals, Inc. (ISIS) Form $392 Million Alliance for Huntington's Disease 4/8/2013
Resverlogix Corporation (RVX.TO) to Spin-Out RVX Therapeutics Inc. (RVX) 4/8/2013
AstraZeneca PLC (AZN) Shells Out $240 Million Upfront for Moderna Therapeutics mRNA Drugs 3/22/2013
bluebird bio Forms Cancer Drug Partnership With Celgene Corporation (CELG) 3/21/2013
Receptos Licenses AbbVie (ABBV) Antibody for Co-Development 3/14/2013
Astellas Pharma Inc. (YPH.BE) and Ambit Biosciences to End Collaboration for Joint Development and Commercialization of FLT3 Kinase Inhibitors 3/13/2013



//-->